Can We Omit Surgery for Low-Risk Ductal Carcinoma In Situ of the Breast?

Affiliations

¹ Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
² Department of Oncology, McMaster University and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada.

Comment

Seema A Khan et al. JAMA. 2025.

. 2025 Mar 18;333(11):948-949.

doi: 10.1001/jama.2025.0088.

¹ Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
² Department of Oncology, McMaster University and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada.

No abstract available

Comment on

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial.
Hwang ES, Hyslop T, Lynch T, Ryser MD, Weiss A, Wolf A, Norris K, Witten M, Grimm L, Schnitt S, Badve S, Factor R, Frank E, Collyar D, Basila D, Pinto D, Watson MA, West R, Davies L, Donovan JL, Shimada A, Li Y, Li Y, Bennett AV, Rosenberg S, Marks J, Winer E, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Carey LA, Thompson AM, Partridge AH; COMET Study Investigators. Hwang ES, et al. JAMA. 2025 Mar 18;333(11):972-980. doi: 10.1001/jama.2024.26698. JAMA. 2025. PMID: 39665585 Free PMC article. Clinical Trial.